EGFR and non-small cell lung carcinoma: For NSCLC patients with brain metastasis, the epidermal growth factor receptor (EGFR) gene mutation status is essential for treatment strategies, such as EGFR-tyrosine kinase inhibitors (EGFR-TKIs) therapy (Guo et al., 2020).